Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination
with lenalidomide in the treatment of Relapsed/Refractory NK/T-cell lymphoma patients who
failed pegaspargase-based regimens.